Page 1

EX - 99.1 2 alks - ex991_7.htm EX - 99.1 Exhibit 99.1 Alkermes Contacts : For Investors : Sandy Coombs For Media : Katie Joyce Alkermes plc Reports Second Quarter 2021 Financial Results +1 781 609 6377 +1 781 249 8927 Second Quarter Revenues of $ 303.7 Million Reflect 23 % Growth Year - Over - Year- Diluted GAAP Earnings per Share of $ 0.01 and Diluted Non - GAAP Earnings per Share of $ 0.30 , Driven by Operational Execution Company Updates Full - Year 2021 Financial Expectations Based on Strong First Half Performance- _ DUBLIN , July 28 , 2021 - Alkermes plc ( Nasdaq : ALKS ) today reported financial results for the second quarter of 2021 and provided updated financial expectations for full - year 2021 . " Alkermes ' strong performance in the second quarter was driven by commercial execution and our focus on profitability . VIVITROL® and ARISTADA® demonstrated robust sequential and year - over - year growth and VUMERITY® continued on an encouraging launch trajectory , ” commented Iain Brown , Chief Financial Officer of Alkermes . " Today , we are raising our financial expectations for full - year 2021 to reflect this performance and anticipated continued strength in the business . We believe that we are in a sound financial position to execute on our business strategy and efficiently invest in our future potential growth drivers . " Quarter Ended June 30 , 2021 Financial Results Revenues Total revenues for the quarter were $ 303.7 million . This compared to $ 247.5 million for the same period in the prior year . Net sales of proprietary products for the quarter were $ 160.8 million , compared to $ 130.4 million for the same period in the prior year . ○ ○ Net sales of VIVITROL were $ 88.4 million , compared to $ 71.6 million for the same period in the prior year , representing an increase of approximately 23 % . Net sales of ARISTADA¹ were $ 72.4 million , compared to $ 58.8 million for the same period in the prior year , representing an increase of approximately 23 % . Manufacturing and royalty revenues for the quarter were $ 142.3 million , compared to $ 116.5 million for the same period in the prior year . о о Costs and Expenses • Manufacturing and royalty revenues from RISPERDAL CONSTA® , INVEGA SUSTENNA® / XEPLION® and INVEGA TRINZA® / TREVICTA® were $ 95.5 million , compared to $ 83.1 million for the same period in the prior year . Manufacturing and royalty revenues from VUMERITY® were $ 20.3 million , compared to $ 2.6 million for the same period in the prior year . Total operating expenses for the quarter were $ 299.3 million , compared to $ 281.2 million for the same period in the prior year . ○ Cost of Goods Manufactured and Sold were $ 53.1 million , compared to $ 45.1 million for the same period in the prior year . о Research and Development ( R & D ) expenses were $ 97.5 million , compared to $ 94.2 million for the same period in the prior year . Selling , General and Administrative ( SG & A ) expenses were $ 139.2 million , compared to $ 132.0 million for the same period in the prior year .